LRP4 and myasthenia gravis: Recently, the low-density lipoprotein receptor-related protein 4 (LRP4), a molecule that forms a complex with MuSK, has been described as a novel auto-antigenic target in about 2% of seronegative MG patients [6], but its clinical significance is still unknown.